Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

MLA

Schneeweiss, Sebastian, et al. “Clinical and Economic Consequences of Reference Pricing for Dihydropyridine Calcium Channel Blockers.” Clinical Pharmacology and Therapeutics, vol. 74, no. 4, Oct. 2003, pp. 388–400. EBSCOhost, https://doi.org/10.1016/S0009-9236(03)00227-3.

APA

Schneeweiss, S., Soumerai, S. B., Maclure, M., Dormuth, C., Walker, A. M., & Glynn, R. J. (2003). Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clinical Pharmacology and Therapeutics, 74(4), 388–400. https://doi.org/10.1016/S0009-9236(03)00227-3

Chicago

Schneeweiss, Sebastian, Stephen B Soumerai, Malcolm Maclure, Colin Dormuth, Alexander M Walker, and Robert J Glynn. 2003. “Clinical and Economic Consequences of Reference Pricing for Dihydropyridine Calcium Channel Blockers.” Clinical Pharmacology and Therapeutics 74 (4): 388–400. doi:10.1016/S0009-9236(03)00227-3.